Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 12/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3528935 | 0.87 | MAPT (0.43) | SLC22A2CYP3A4TMEM97ABCG2MAPT | |
| SCHEMBL3520763 | 0.86 | TP53 (0.49) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL3528408 | 0.85 | SLC22A2 (0.43) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL14129795 | 0.85 | SLC22A2 (0.43) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Hydrochloric Acid SCHEMBL4319293 | 0.85 | SLC22A2 (0.43) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL2184805 | 0.85 | SLC22A2 (0.44) | SLC22A2CYP3A4TMEM97ABCG2MAPT | |
| SCHEMBL82568 | 0.84 | LIPG (0.46) | SLC22A2MAPTLIPG | |
| SCHEMBL22482699 | 0.84 | MAPT (0.44) | SLC22A2CYP3A4TMEM97ABCG2MAPT | |
| SCHEMBL3523953 | 0.84 | SLC22A2 (0.42) | SLC22A2CYP3A4TMEM97ABCG2MAPT | |
| SCHEMBL2238354 | 0.84 | LIPG (0.44) | SLC22A2CYP3A4TMEM97ABCG2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188271-B2 | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-7858788-B2 | Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20090143356-A1 | Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143356-A1 | Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity | CDK20, CYP4A22, CDK10 | SLC22A2 503/4885CYP3A4 484/4885TMEM97 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.